09:01 EDT 21st March 2018 | BioPortfolio

Harvey Nash was founded in London in 1988. David Higgins, the current Executive Vice Chairman, was one of the original founders and still has a sizeable financial stake in the company. Early on, the management broadened the Group’s geographical coverage and increased the range of services, recognising the value this would add to the business in the longer term.

An IPO in April 1997 facilitated a fresh injection of capital into the business, fast tracking expansion into Europe, the USA and Asia. This was achieved through a mix of acquisitions and organic growth.

Today, Harvey Nash holds a unique position as the only truly global IT recruitment business listed on the London Stock Exchange with over 3,000 employees and contractors working across 28 offices worldwide


13 Bruton Street
United Kingdom


Phone: 44 (0)20 7333 0033
Fax: 44 (0)20 7333 0032

News Articles [703 Associated News Articles listed on BioPortfolio]

Harvey Fierstein Responds To Being Mistaken For Harvey Weinstein

Harvey Fierstein has been inadvertently thrust into a sexual harassment scandal that’s shaken up Hollywood.

Cecil McCrory’s Newly Released “Julia’s Adventures With Harvey and Tinker Belle: Julia Meets Harvey” is a Delightful Tale That Tells a Valuable Lesson for a Lifetime

(PRWEB) October 12, 2017 “Julia’s Adventures with Harvey and Tinker Belle: Julia Meets Harvey”: a charming narrative...

Texas Flood: Researchers Compare Pollution Levels before and after Hurricane Harvey

In the laboratory, researchers extracted organic compounds from the pre-Harvey dust and post-Harvey soil samples and analyzed them using gas chromatography

The Race To Find A Treatment For NASH

Although there are a number of investigational NASH therapies in various stages of development, there is no approved drug yet for this silent killer. However, the fact that the race to develop an effe...

Emerging pharmacologic approach may inhibit NASH

Treating a liver disease called NASH (non-alcoholic steatohepatitis), which affects 10 to 15 percent of obese individuals with type-2 diabetes worldwide, is difficult. But now scientists believe they ...

[Comment] FGF-19 agonism for NASH: a short study of a long disease

Non-alcoholic steatohepatitis (NASH) has emerged as the most common cause of liver disease worldwide and is on a trajectory to become the most common indication for liver transplantation.1,2 Interest ...

Behind The NASH Leaders, Pursuers Already Anticipating Second-Wave Improvements

Privately held Cirius and NGM and big pharma Bristol-Myers Squibb are in Phase II for NASH with programs also working...   

Boehringer Ingelheim Partners with Target PharmaSolutions to Progress NASH Research

CHAPEL HILL, N.C., Oct. 19, 2017 /PRNewswire/ — TARGET PharmaSolutions, Inc., a real-world clinical data company, is pleased to announce that Boehringer Ingelheim International GmbH has entered ...

PubMed Articles [1959 Associated PubMed Articles listed on BioPortfolio]

Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model.

The incidence of nonalcoholic steatohepatitis (NASH) is increasing. The pathophysiological mechanisms of NASH and the sequence of events leading to hepatic fibrosis are incompletely understood. The ai...

Nation-wide trends in non-alcoholic steatohepatitis (NASH) in patients with and without diabetes between 2004-05 and 2014-15 in England.

There are no national studies evaluating the epidemiology of non-alcoholic steatohepatitis (NASH) in England. NASH is becoming an increasingly important health issue given the inexorable rise in obesi...

The Role of Metabolic Surgery in Non-alcoholic Steatohepatitis Improvement.

Non-alcoholic fatty liver disease (NAFLD) is frequently associated with obesity and overweight. It has a broad spectrum of clinical and histological presentations, such as steatosis, inflammation (kno...

Bile acid alterations are associated with insulin resistance, but not with NASH in obese subjects.

Bile acids (BA) are signalling molecules controlling energy homeostasis which can be both toxic and protective for the liver. BA alterations have been reported in obesity, insulin resistance (IR) and ...

The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease: When to Biopsy and in Whom.

Nonalcoholic fatty liver disease (NAFLD) is a common liver disorder that can be divided into benign steatosis or nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). Elastography a...

Clinical Trials [3660 Associated Clinical Trials listed on BioPortfolio]

Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH

CP-945598 is a potent and selective Cannabinoid-1 (CB1) receptor antagonist currently being developed for the treatment of obesity. CP-945598 is also being considered as a potential treat...

Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

The primary objective of this study is the proof of mechanism and support of dose finding, together with the safety evaluation in patients with clinical evidence of NASH. To gain further ...

A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)

TARGET-NASH is a longitudinal observational cohort study of patients being managed for NAFLD or NASH in usual clinical practice. TARGET-NASH will create a research registry of patients wit...

Protocol for the Assessment of Variability in Histology and Gene Expression in Bariatric Surgery Patients.

It is known that a vast majority of patients seeking a bariatric surgery weight reduction procedure have non-alcoholic fatty liver disease (NAFLD), while a smaller subset of patients withi...

Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

The purpose of the present study is to assess the effects of LMB763 with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH

Companies [1633 Associated Companies listed on BioPortfolio]


Harvey Nash was founded in London in 1988. David Higgins, the current Executive Vice Chairman, was one of the original founders and still has a sizeable financial stake in the company. Early on, the m...

Nash Finch Company

Patricia Nash

The quintessential embodiment of style, form and function, Patricia Nash Designs creates handbags and accessories that are made of beautiful, vegetable tanned Italian leather. The...

Harvey & Company LLC

Harvey & Company has a long track record of successful investments and acquisitions across a variety of manufacturing, business service and distribution sectors. Our success is based on the recognitio...

North American Specialty Hospital

Headquartered in Denver, NASH is a US majority-owned and managed enterprise. Incorporating US physicians in its service delivery, NASH is designed to provide pre-operative and pos...

More Information about "HARVEY NASH GROUP" on BioPortfolio

We have published hundreds of HARVEY NASH GROUP news stories on BioPortfolio along with dozens of HARVEY NASH GROUP Clinical Trials and PubMed Articles about HARVEY NASH GROUP for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of HARVEY NASH GROUP Companies in our database. You can also find out about relevant HARVEY NASH GROUP Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record